About Bharat Parenterals Limited
Data last updated: 05 January 2026
Bharat Parenterals Limited is a public limited company based in Vadodara, Gujarat, India. It specialises in drug formulation and development, a part of the broader pharmaceuticals sector. Incorporated on 03 September 1992, the company has been in operation for over 34 years.
Registered with ROC Ahmedabad under CIN L24231GJ1992PLC018237. Listed on BSE: 541096.
Capital: an authorised share capital of ₹8 Cr and a paid-up capital of ₹6.89 Cr. It is led by directors including Mukeshbhai Jivrajbhai Patel and Bharatkumar Rameshchandra Desai.
Last AGM: 26 September 2025. Financial statements filed for year ended 31 March 2025. Office: Survey No. 144A Jarod – Samlaya Road Haripura Savli, Vadodara, Gujarat, India – 391520.
As per the financials filed for FY 2025, the company reported a revenue of ₹352 Cr, a growth of 32% compared to the previous year.
The company has a workforce of approximately 396 employees as per the latest available data. Its group structure includes 2 subsidiaries.
The company is associated with 1 brand - Bharat Parenterals. As per MCA filings, the company has open charges of ₹131.7 Cr and satisfied charges of ₹34.12 Cr on record.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website bplindia.in.
-
Email*****@*****.com
-
Telephone+91-****-******
-
Website
-
Social Media
-
Registered AddressSurvey No. 144A Jarod – Samlaya Road Haripura Savli, Vadodara, Gujarat, India – 391520
-
IndustryPharma, Drug Formulation & Development
- Historical Financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Litigation, compliance and MCA filings
- PDF report delivered after checkout
CIN History of Bharat Parenterals Limited
Bharat Parenterals Limited has one previous CIN (Corporate Identification Number): U24231GJ1992PLC018237. The current CIN is L24231GJ1992PLC018237, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| L24231GJ1992PLC018237 | Current |
| U24231GJ1992PLC018237 | Previous |
Associated Brands with Bharat Parenterals Limited
Bharat Parenterals Limited operates one associated brand: Bharat Parenterals. These brands represent Bharat Parenterals Limited's diversified market presence and brand portfolio.
| Brand | Description | Website |
|---|---|---|
| Pharmaceutical formulations are manufactured for domestic and international markets. | bplindia.in |
Competitors & Alternatives of Bharat Parenterals Limited
Brands and companies operating in the same space as Bharat Parenterals Limited include Jubilant Life Sciences, Akums, Nectar Lifesciences and 5 more.
| Competitor | Description | Location | Founded |
|---|---|---|---|
|
|
Company offering a suite of R&D and manufacturing services for small molecules and generics | Noida, India, India | 1978 |
|
|
CDMO focusing on spectrum of dosage forms and therapeutic segments | Delhi, India, India | 2004 |
|
|
Cephalosporin APIs and generic formulations are manufactured. | Chandigarh, India, India | 1995 |
|
|
Biopharma regulatory affairs, quality control, and strategy services are provided. | Gurugram, India, India | 2001 |
|
|
Contract development and manufacturing organization for proprietary and generic drugs | Paris, France, France | 1993 |
|
|
Pharmaceutical development and manufacturing services are offered contractually. | Jordbro, Sweden, Sweden | 1995 |
|
|
CDMO with a focus on early phase drug product development | Clearwater, United States, United States | 2006 |
|
|
Topical and inhaled drug delivery formulations are developed and manufactured. | Guildford, United Kingdom, United Kingdom | 1998 |
Business Activity of Bharat Parenterals Limited
Bharat Parenterals Limited is engaged in the principal business activity of manufacturing, with detailed activities including chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products | ********* |
Auditor Details of Bharat Parenterals Limited
Bharat Parenterals Limited is audited by M/s Shah Mehta & Bakshi (ICAI peer reviewed, certificate valid till 2028-07-31) for the financial year 2026, as reported in its BSE exchange filings. The statutory auditor is responsible for expressing an independent opinion on whether the financial statements present a true and fair view in accordance with applicable accounting standards.
| Name | Financial year | Audit opinion |
|---|---|---|
| M/s Shah Mehta & Bakshi (ICAI peer reviewed, certificate valid till 2028-07-31) | FY 2026 | Declaration of unmodified opinion |
Board of Directors of Bharat Parenterals Limited
Bharat Parenterals Limited is currently managed by 8 directors, with 17 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Mukeshbhai Jivrajbhai Patel | Director | 26 Sep 2020 | 5 Years 9 Months | Current |
| Bharatkumar Rameshchandra Desai | Managing Director | 03 Sep 1992 | 33 Years 10 Months | Current |
|
Shaileshkumar Ghabhawala
Also directs:
S.L. Infrabuildcon Private Limited
|
Director | 03 Aug 2017 | 8 Years 11 Months | Current |
|
Zankhana Bimalkumar Sheth
Also directs:
Innoxel Lifesciences Private Limited
|
Director | 14 Aug 2018 | 7 Years 10 Months | Current |
| Hemang Jayendrabhai Shah | Director | 08 Jul 2010 | 16 Years 0 Months | Current |
| Alkesh Jayantilal Shah | Additional Director | 28 Jul 2025 | 0 Years 11 Months | Current |
Financials of Bharat Parenterals Limited FY 2026 filings available
Bharat Parenterals Limited reported revenue of ₹345.43 Cr (up 1.48% YoY) for FY 2026. Profit growth despite declining revenue indicates effective cost management and margin discipline.
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | ₹345.43 Cr | ₹340.38 Cr | ₹257.36 Cr | ₹217.98 Cr | ₹212.01 Cr | ₹204.64 Cr | ₹228.18 Cr | ₹219.54 Cr |
| Other Income | ₹9.54 Cr | ₹11.9 Cr | ₹8.59 Cr | ₹11.74 Cr | ₹7.78 Cr | ₹8.68 Cr | ₹11.48 Cr | ₹12.7 Cr |
| Total Income | ₹354.98 Cr | ₹352.28 Cr | ₹265.95 Cr | ₹229.72 Cr | ₹219.79 Cr | ₹213.32 Cr | ₹239.66 Cr | ₹232.25 Cr |
| Cost of Materials Consumed | ₹169.26 Cr | ₹178.17 Cr | ₹173.16 Cr | ₹146.07 Cr | ₹132.72 Cr | ₹127.13 Cr | ₹130.73 Cr | ₹95.97 Cr |
| Purchases of Stock-in-Trade | ₹17.41 Cr | ₹7.76 Cr | ₹38 Lakh | ₹1.16 Cr | ₹1.66 Cr | ₹5.33 Cr | ₹21.15 Cr | ₹46.12 Cr |
| Changes in Inventories | ₹4.73 Cr | -₹45 Lakh | -₹15.18 Cr | -₹9.75 Cr | ₹1.68 Cr | ₹1.8 Cr | -₹2.97 Cr | -₹1.61 Cr |
| Employee Benefit Expense | ₹67.28 Cr | ₹49.66 Cr | ₹22.78 Cr | ₹18 Cr | ₹15.37 Cr | ₹14.75 Cr | ₹15.58 Cr | ₹15.37 Cr |
| Finance Costs | ₹12.53 Cr | ₹13.23 Cr | ₹3.22 Cr | ₹2.19 Cr | ₹89 Lakh | ₹77 Lakh | ₹86 Lakh | ₹86.99 Lakh |
| Depreciation & Amortisation | ₹34.25 Cr | ₹35.32 Cr | ₹9.02 Cr | ₹5.88 Cr | ₹6.66 Cr | ₹6.03 Cr | ₹5.88 Cr | ₹6.13 Cr |
| Other Expenses | ₹70.94 Cr | ₹102.54 Cr | ₹53.85 Cr | ₹42.62 Cr | ₹32.93 Cr | ₹30.39 Cr | ₹35.62 Cr | ₹34.81 Cr |
| Total Expenses | ₹376.4 Cr | ₹386.23 Cr | ₹247.23 Cr | ₹206.17 Cr | ₹191.91 Cr | ₹186.2 Cr | ₹206.85 Cr | ₹197.65 Cr |
| Profit Before Exceptional Items & Tax | -₹21.42 Cr | -₹33.95 Cr | ₹18.72 Cr | ₹23.55 Cr | ₹27.88 Cr | ₹27.12 Cr | ₹32.81 Cr | ₹34.59 Cr |
| Exceptional Items | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Profit Before Tax | -₹21.42 Cr | -₹33.95 Cr | ₹18.72 Cr | ₹23.55 Cr | ₹27.88 Cr | ₹27.12 Cr | ₹32.81 Cr | ₹34.59 Cr |
| Total Tax Expense | ₹5.88 Cr | ₹9.22 Cr | ₹8.23 Cr | ₹7.83 Cr | ₹7.07 Cr | ₹6.81 Cr | ₹8.65 Cr | ₹13.35 Cr |
| Net Profit | -₹27.31 Cr | -₹43.68 Cr | ₹10.52 Cr | ₹15.72 Cr | ₹20.81 Cr | ₹20.31 Cr | ₹24.16 Cr | ₹21.25 Cr |
| attributable to Owners | -₹8.19 Cr | ₹0 | - | ₹16.44 Cr | ₹21.05 Cr | ₹20.39 Cr | ₹0 | ₹0 |
| attributable to NCI | -₹19.12 Cr | ₹0 | - | -₹68 Lakh | -₹24 Lakh | -₹7 Lakh | ₹0 | ₹0 |
| Other Comprehensive Income | ₹57.72 Lakh | ₹20 Lakh | -₹20 Lakh | ₹4 Lakh | -₹23 Lakh | ₹16 Lakh | ₹4 Lakh | -₹8.8 Lakh |
| Total Comprehensive Income | -₹26.73 Cr | -₹43.48 Cr | ₹10.32 Cr | ₹15.76 Cr | ₹20.58 Cr | ₹20.47 Cr | ₹24.2 Cr | ₹21.16 Cr |
| EBITDA (computed) | ₹25.36 Cr | ₹14.6 Cr | ₹30.96 Cr | ₹31.62 Cr | ₹35.43 Cr | ₹33.92 Cr | ₹39.55 Cr | ₹41.59 Cr |
| Basic EPS | ₹-39.62 | ₹-66.64 | ₹8.65 | ₹28.40 | ₹36.67 | ₹35.59 | ₹42.14 | ₹37.08 |
| Diluted EPS | ₹-39.62 | ₹-66.64 | ₹0.00 | ₹28.40 | ₹36.67 | ₹35.59 | ₹42.14 | ₹37.08 |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | ₹613.3 Cr | ₹648.53 Cr | ₹503.81 Cr | ₹350.34 Cr | ₹226.06 Cr | ₹198.65 Cr | ₹187.5 Cr | ₹158.93 Cr |
| Non-current Assets | ₹300.26 Cr | ₹292.5 Cr | ₹243.9 Cr | ₹166.06 Cr | ₹82.32 Cr | ₹50.62 Cr | ₹55.88 Cr | ₹40.91 Cr |
| Current Assets | ₹313.04 Cr | ₹356.03 Cr | ₹259.91 Cr | ₹184.28 Cr | ₹143.74 Cr | ₹148.03 Cr | ₹131.62 Cr | ₹118.02 Cr |
| Property, Plant & Equipment | ₹201.6 Cr | ₹198.88 Cr | ₹209.48 Cr | ₹41.19 Cr | ₹39.75 Cr | ₹43.36 Cr | ₹31.75 Cr | ₹33.98 Cr |
| Inventories | ₹84.72 Cr | ₹71.95 Cr | ₹61.47 Cr | ₹37.84 Cr | ₹20.76 Cr | ₹22.43 Cr | ₹28.82 Cr | ₹22.52 Cr |
| Trade Receivables | ₹150.65 Cr | ₹171.74 Cr | ₹141.42 Cr | ₹112.41 Cr | ₹73.4 Cr | ₹67.83 Cr | ₹79.35 Cr | ₹63.87 Cr |
| Cash & Equivalents | ₹1.48 Cr | ₹56 Lakh | ₹8.71 Cr | ₹7.85 Cr | ₹3.4 Cr | ₹1.68 Cr | ₹10.1 Cr | ₹11.07 Cr |
| Equity (Net Worth) | ₹311.58 Cr | ₹339 Cr | ₹238.18 Cr | ₹217.89 Cr | ₹170.14 Cr | ₹143.82 Cr | ₹118.19 Cr | ₹94.01 Cr |
| Equity Share Capital | ₹6.89 Cr | ₹6.89 Cr | ₹5.82 Cr | ₹5.77 Cr | ₹5.77 Cr | ₹5.73 Cr | ₹5.73 Cr | ₹5.73 Cr |
| Borrowings (Non-current) | ₹121.79 Cr | ₹75.87 Cr | ₹0 | ₹10.92 Cr | ₹12.49 Cr | ₹8.59 Cr | ₹71 Lakh | ₹96.5 Lakh |
| Borrowings (Current) | ₹24.32 Cr | ₹104.33 Cr | ₹84.41 Cr | ₹38.82 Cr | ₹5.26 Cr | ₹1.19 Cr | ₹0 | ₹1.95 Cr |
| Total Debt (computed) | ₹146.11 Cr | ₹180.2 Cr | ₹84.41 Cr | ₹49.74 Cr | ₹17.75 Cr | ₹9.78 Cr | ₹71 Lakh | ₹2.92 Cr |
| Current Liabilities | ₹157.39 Cr | ₹219.3 Cr | ₹190.37 Cr | ₹119.8 Cr | ₹41.53 Cr | ₹43.63 Cr | ₹65.89 Cr | ₹60.51 Cr |
| Total Liabilities | ₹301.72 Cr | ₹309.53 Cr | ₹265.63 Cr | ₹132.45 Cr | ₹55.92 Cr | ₹54.83 Cr | ₹69.31 Cr | ₹64.92 Cr |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Operating Cash Flow | ₹38.36 Cr | -₹14.39 Cr | -₹4.71 Cr | ₹21.66 Cr | -₹1.07 Cr |
| Investing Cash Flow | ₹9.32 Cr | -₹137.12 Cr | -₹104.78 Cr | -₹77.82 Cr | -₹6.63 Cr |
| Financing Cash Flow | -₹47.05 Cr | ₹156.09 Cr | ₹110.43 Cr | ₹60.6 Cr | ₹9.42 Cr |
| Capital Expenditure | ₹39.93 Cr | ₹29.08 Cr | ₹104.3 Cr | ₹91.6 Cr | ₹38.95 Cr |
| Free Cash Flow (computed) | -₹1.57 Cr | -₹43.47 Cr | -₹109.01 Cr | -₹69.94 Cr | -₹40.02 Cr |
| Dividends Paid | ₹68.75 Lakh | ₹58 Lakh | ₹43 Lakh | ₹0 | ₹0 |
| Net Change in Cash | ₹63.61 Lakh | ₹4.46 Cr | ₹94 Lakh | ₹4.44 Cr | ₹1.72 Cr |
| Metrics | Q4 FY26 | Q3 FY26 | Q2 FY26 | Q1 FY26 | Q4 FY25 | Q3 FY25 | Q2 FY25 | Q1 FY25 |
|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | ₹99.62 Cr | ₹65.19 Cr | ₹64.62 Cr | ₹116 Cr | ₹103.98 Cr | ₹72.26 Cr | ₹71.63 Cr | ₹92.51 Cr |
| Other Income | ₹3.63 Cr | ₹1.33 Cr | ₹3.53 Cr | ₹1.06 Cr | ₹2.2 Cr | ₹2.95 Cr | ₹4.21 Cr | ₹2.54 Cr |
| Total Income | ₹103.25 Cr | ₹66.52 Cr | ₹68.15 Cr | ₹117.06 Cr | ₹106.18 Cr | ₹75.21 Cr | ₹75.84 Cr | ₹95.05 Cr |
| Cost of Materials Consumed | ₹51.35 Cr | ₹26.11 Cr | ₹31.41 Cr | ₹54.83 Cr | ₹51.18 Cr | ₹45.25 Cr | ₹26.94 Cr | ₹54.8 Cr |
| Purchases of Stock-in-Trade | ₹5.8 Cr | ₹3.66 Cr | ₹4.73 Cr | ₹3.21 Cr | ₹6.64 Cr | ₹48 Lakh | ₹0 | ₹64 Lakh |
| Changes in Inventories | ₹60.36 Lakh | ₹2.53 Cr | -₹9.22 Cr | ₹10.81 Cr | -₹4.28 Cr | -₹10.06 Cr | ₹14.76 Cr | -₹87 Lakh |
| Employee Benefit Expense | ₹18.46 Cr | ₹17.03 Cr | ₹16.49 Cr | ₹15.3 Cr | ₹18.14 Cr | ₹10.98 Cr | ₹10.62 Cr | ₹9.92 Cr |
| Finance Costs | ₹2.85 Cr | ₹2.9 Cr | ₹3.11 Cr | ₹3.69 Cr | ₹4.22 Cr | ₹3.33 Cr | ₹2.91 Cr | ₹2.77 Cr |
| Depreciation & Amortisation | ₹8.63 Cr | ₹8.46 Cr | ₹8.56 Cr | ₹8.6 Cr | ₹8.52 Cr | ₹8.76 Cr | ₹9.01 Cr | ₹9.03 Cr |
| Other Expenses | ₹23.94 Cr | ₹14.11 Cr | ₹20.39 Cr | ₹18.08 Cr | ₹30.06 Cr | ₹21.97 Cr | ₹26.98 Cr | ₹23.53 Cr |
| Total Expenses | ₹111.62 Cr | ₹74.8 Cr | ₹75.47 Cr | ₹114.52 Cr | ₹114.48 Cr | ₹80.71 Cr | ₹91.22 Cr | ₹99.82 Cr |
| Profit Before Exceptional Items & Tax | -₹8.37 Cr | -₹8.28 Cr | -₹7.32 Cr | ₹2.54 Cr | -₹8.3 Cr | -₹5.5 Cr | -₹15.38 Cr | -₹4.77 Cr |
| Exceptional Items | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Profit Before Tax | -₹8.37 Cr | -₹8.28 Cr | -₹7.32 Cr | ₹2.54 Cr | -₹8.3 Cr | -₹5.5 Cr | -₹15.38 Cr | -₹4.77 Cr |
| Total Tax Expense | -₹21.19 Lakh | ₹1.39 Cr | ₹1.29 Cr | ₹3.41 Cr | ₹96 Lakh | ₹2.37 Cr | ₹2.14 Cr | ₹4.08 Cr |
| Net Profit | -₹8.16 Cr | -₹9.67 Cr | -₹8.61 Cr | -₹87 Lakh | -₹9.44 Cr | -₹7.87 Cr | -₹17.52 Cr | -₹8.85 Cr |
| attributable to Owners | -₹4.8 Cr | -₹4.39 Cr | -₹7.24 Cr | ₹0 | ₹0 | -₹1.68 Cr | -₹7.56 Cr | - |
| attributable to NCI | -₹3.36 Cr | -₹5.28 Cr | -₹1.37 Cr | ₹0 | ₹0 | -₹6.21 Cr | -₹10.01 Cr | - |
| Other Comprehensive Income | ₹21.41 Lakh | ₹33.42 Lakh | ₹6 Lakh | -₹4 Lakh | ₹35 Lakh | -₹5 Lakh | -₹5 Lakh | -₹5 Lakh |
| Total Comprehensive Income | -₹7.95 Cr | -₹9.34 Cr | -₹8.55 Cr | -₹91 Lakh | -₹9.09 Cr | -₹7.92 Cr | -₹17.57 Cr | -₹8.9 Cr |
| EBITDA (computed) | ₹3.1 Cr | ₹3.07 Cr | ₹4.35 Cr | ₹14.83 Cr | ₹4.44 Cr | ₹6.59 Cr | -₹3.46 Cr | ₹7.03 Cr |
| Basic EPS | ₹-11.84 | ₹-14.03 | ₹-14.00 | ₹-1.27 | ₹-14.40 | ₹-10.00 | ₹-27.00 | ₹-14.71 |
| Diluted EPS | ₹-11.84 | ₹-14.03 | ₹-14.00 | ₹-1.27 | ₹-14.40 | ₹-10.00 | ₹-27.00 | ₹0.00 |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | ₹234.01 Cr | ₹304.13 Cr | ₹254.16 Cr | ₹217.98 Cr | ₹212.01 Cr | ₹203.67 Cr | ₹226.33 Cr | ₹219.69 Cr |
| Other Income | ₹12.55 Cr | ₹14.56 Cr | ₹11.96 Cr | ₹18.84 Cr | ₹7.78 Cr | ₹8.67 Cr | ₹11.48 Cr | ₹12.7 Cr |
| Total Income | ₹246.57 Cr | ₹318.69 Cr | ₹266.12 Cr | ₹236.82 Cr | ₹219.79 Cr | ₹212.34 Cr | ₹237.81 Cr | ₹232.39 Cr |
| Cost of Materials Consumed | ₹148.9 Cr | ₹178.34 Cr | ₹173.16 Cr | ₹146.07 Cr | ₹132.72 Cr | ₹127.13 Cr | ₹130.73 Cr | ₹95.97 Cr |
| Purchases of Stock-in-Trade | ₹1 Cr | ₹1.13 Cr | ₹41 Lakh | ₹1.16 Cr | ₹1.66 Cr | ₹5.02 Cr | ₹19.77 Cr | ₹45.37 Cr |
| Changes in Inventories | ₹2.05 Cr | ₹10.14 Cr | -₹15.18 Cr | -₹9.75 Cr | ₹1.68 Cr | ₹1.88 Cr | -₹3.27 Cr | -₹19.13 Lakh |
| Employee Benefit Expense | ₹25.13 Cr | ₹21.38 Cr | ₹19.61 Cr | ₹16.93 Cr | ₹15.26 Cr | ₹14.39 Cr | ₹14.11 Cr | ₹14.27 Cr |
| Finance Costs | ₹3.44 Cr | ₹4.79 Cr | ₹3.19 Cr | ₹2.19 Cr | ₹89 Lakh | ₹76 Lakh | ₹86 Lakh | ₹86.69 Lakh |
| Depreciation & Amortisation | ₹8.36 Cr | ₹7.05 Cr | ₹6.4 Cr | ₹5.85 Cr | ₹6.66 Cr | ₹6.03 Cr | ₹5.88 Cr | ₹6.13 Cr |
| Other Expenses | ₹35.84 Cr | ₹59.54 Cr | ₹47.73 Cr | ₹42.2 Cr | ₹32.55 Cr | ₹30.11 Cr | ₹34.77 Cr | ₹34.06 Cr |
| Total Expenses | ₹224.72 Cr | ₹282.37 Cr | ₹235.32 Cr | ₹204.65 Cr | ₹191.42 Cr | ₹185.32 Cr | ₹202.85 Cr | ₹196.47 Cr |
| Profit Before Exceptional Items & Tax | ₹21.84 Cr | ₹36.32 Cr | ₹30.8 Cr | ₹32.17 Cr | ₹28.37 Cr | ₹27.02 Cr | ₹34.96 Cr | ₹35.92 Cr |
| Exceptional Items | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Profit Before Tax | ₹21.84 Cr | ₹36.32 Cr | ₹30.8 Cr | ₹32.17 Cr | ₹28.37 Cr | ₹27.02 Cr | ₹34.96 Cr | ₹35.92 Cr |
| Total Tax Expense | ₹5.82 Cr | ₹9.36 Cr | ₹8.24 Cr | ₹7.83 Cr | ₹7.07 Cr | ₹6.81 Cr | ₹8.65 Cr | ₹13.35 Cr |
| Net Profit | ₹16.02 Cr | ₹26.45 Cr | ₹22.59 Cr | ₹24.34 Cr | ₹21.3 Cr | ₹20.21 Cr | ₹26.31 Cr | ₹22.57 Cr |
| Other Comprehensive Income | ₹18.66 Lakh | ₹6 Lakh | -₹20 Lakh | ₹4 Lakh | -₹23 Lakh | ₹16 Lakh | ₹4 Lakh | -₹8.8 Lakh |
| Total Comprehensive Income | ₹16.21 Cr | ₹26.51 Cr | ₹22.39 Cr | ₹24.38 Cr | ₹21.07 Cr | ₹20.37 Cr | ₹26.35 Cr | ₹22.49 Cr |
| EBITDA (computed) | ₹33.64 Cr | ₹48.16 Cr | ₹40.39 Cr | ₹40.21 Cr | ₹35.92 Cr | ₹33.81 Cr | ₹41.7 Cr | ₹42.91 Cr |
| Basic EPS | ₹23.24 | ₹40.36 | ₹8.65 | ₹42.40 | ₹37.11 | ₹35.27 | ₹45.90 | ₹39.40 |
| Diluted EPS | ₹23.24 | ₹40.36 | ₹0.00 | ₹42.40 | ₹37.11 | ₹35.27 | ₹45.90 | ₹39.40 |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | ₹519.94 Cr | ₹549.19 Cr | ₹387.15 Cr | ₹308.03 Cr | ₹218 Cr | ₹196.24 Cr | ₹192.3 Cr | ₹161.27 Cr |
| Non-current Assets | ₹299.77 Cr | ₹283.41 Cr | ₹168.99 Cr | ₹133.52 Cr | ₹74.64 Cr | ₹49.21 Cr | ₹56.12 Cr | ₹41.14 Cr |
| Current Assets | ₹220.17 Cr | ₹265.78 Cr | ₹218.16 Cr | ₹174.51 Cr | ₹143.36 Cr | ₹147.03 Cr | ₹136.18 Cr | ₹120.13 Cr |
| Property, Plant & Equipment | ₹49.8 Cr | ₹45.37 Cr | ₹38.46 Cr | ₹35.28 Cr | ₹39.75 Cr | ₹43.36 Cr | ₹31.75 Cr | ₹33.98 Cr |
| Inventories | ₹54.33 Cr | ₹46.85 Cr | ₹54.43 Cr | ₹37.84 Cr | ₹20.76 Cr | ₹22.43 Cr | ₹27.69 Cr | ₹21.1 Cr |
| Trade Receivables | ₹120.57 Cr | ₹164.72 Cr | ₹139.78 Cr | ₹112.4 Cr | ₹73.4 Cr | ₹67.83 Cr | ₹81.7 Cr | ₹65.65 Cr |
| Cash & Equivalents | ₹51.99 Lakh | ₹34 Lakh | ₹1.43 Cr | ₹6.35 Cr | ₹3.33 Cr | ₹1.4 Cr | ₹9.69 Cr | ₹10.88 Cr |
| Equity (Net Worth) | ₹402.34 Cr | ₹386.82 Cr | ₹213.61 Cr | ₹191.06 Cr | ₹166.15 Cr | ₹143.94 Cr | ₹123.14 Cr | ₹96.8 Cr |
| Equity Share Capital | ₹6.89 Cr | ₹6.89 Cr | ₹5.82 Cr | ₹5.77 Cr | ₹5.77 Cr | ₹5.73 Cr | ₹5.73 Cr | ₹5.73 Cr |
| Borrowings (Non-current) | ₹13.64 Cr | ₹2.27 Cr | ₹3.66 Cr | ₹6.89 Cr | ₹9.75 Cr | ₹8.59 Cr | ₹71 Lakh | ₹96.5 Lakh |
| Borrowings (Current) | ₹6.42 Cr | ₹62.48 Cr | ₹79.36 Cr | ₹38.82 Cr | ₹5.26 Cr | ₹1.19 Cr | ₹0 | ₹1.95 Cr |
| Total Debt (computed) | ₹20.07 Cr | ₹64.75 Cr | ₹83.02 Cr | ₹45.71 Cr | ₹15.01 Cr | ₹9.78 Cr | ₹71 Lakh | ₹2.92 Cr |
| Current Liabilities | ₹101.87 Cr | ₹154.63 Cr | ₹167.78 Cr | ₹108.35 Cr | ₹40.21 Cr | ₹41.1 Cr | ₹65.74 Cr | ₹60.05 Cr |
| Total Liabilities | ₹117.6 Cr | ₹162.37 Cr | ₹173.54 Cr | ₹116.97 Cr | ₹51.85 Cr | ₹52.3 Cr | ₹69.16 Cr | ₹64.47 Cr |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Operating Cash Flow | ₹44.57 Cr | ₹47.67 Cr | -₹22.91 Cr | -₹11.56 Cr | -₹22.15 Cr |
| Investing Cash Flow | ₹4.14 Cr | ₹89.7 Cr | -₹16.1 Cr | -₹13.95 Cr | ₹21.76 Cr |
| Financing Cash Flow | -₹48.8 Cr | ₹69.25 Cr | ₹34.17 Cr | ₹28.52 Cr | ₹2.32 Cr |
| Capital Expenditure | ₹14.52 Cr | -₹20.3 Cr | ₹10.36 Cr | ₹5.06 Cr | ₹4.76 Cr |
| Free Cash Flow (computed) | ₹30.04 Cr | ₹27.37 Cr | -₹33.27 Cr | -₹16.62 Cr | -₹26.91 Cr |
| Dividends Paid | ₹68.92 Lakh | ₹58 Lakh | ₹39.47 Lakh | ₹0 | ₹0 |
| Net Change in Cash | -₹9.62 Lakh | ₹205.41 Cr | -₹4.83 Cr | ₹3 Cr | ₹1.93 Cr |
| Metrics | Q4 FY26 | Q3 FY26 | Q2 FY26 | Q1 FY26 | Q4 FY25 | Q3 FY25 | Q2 FY25 | Q1 FY25 |
|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | ₹56.54 Cr | ₹41.41 Cr | ₹41.7 Cr | ₹94.37 Cr | ₹80.28 Cr | ₹67.34 Cr | ₹64.45 Cr | ₹92.06 Cr |
| Other Income | ₹4.44 Cr | ₹2.28 Cr | ₹4.21 Cr | ₹1.62 Cr | ₹2.26 Cr | ₹3.79 Cr | ₹4.6 Cr | ₹3.9 Cr |
| Total Income | ₹60.98 Cr | ₹43.69 Cr | ₹45.91 Cr | ₹95.99 Cr | ₹82.54 Cr | ₹71.13 Cr | ₹69.05 Cr | ₹95.96 Cr |
| Cost of Materials Consumed | ₹41.97 Cr | ₹20.82 Cr | ₹31.28 Cr | ₹54.83 Cr | ₹51.35 Cr | ₹45.25 Cr | ₹26.93 Cr | ₹54.8 Cr |
| Purchases of Stock-in-Trade | ₹68.88 Lakh | ₹31.26 Lakh | ₹0 | ₹0 | ₹0 | ₹49 Lakh | ₹0 | ₹64 Lakh |
| Changes in Inventories | -₹1.98 Cr | ₹3.99 Cr | -₹7.97 Cr | ₹8 Cr | ₹3.54 Cr | -₹7.56 Cr | ₹14.76 Cr | -₹59 Lakh |
| Employee Benefit Expense | ₹6.14 Cr | ₹6.52 Cr | ₹6.51 Cr | ₹5.96 Cr | ₹5.67 Cr | ₹5.29 Cr | ₹5.42 Cr | ₹4.99 Cr |
| Finance Costs | ₹51.47 Lakh | ₹54.8 Lakh | ₹96 Lakh | ₹1.42 Cr | ₹1.48 Cr | ₹1.41 Cr | ₹88 Lakh | ₹1.02 Cr |
| Depreciation & Amortisation | ₹2.04 Cr | ₹2.1 Cr | ₹2.17 Cr | ₹2.06 Cr | ₹1.82 Cr | ₹1.86 Cr | ₹1.75 Cr | ₹1.61 Cr |
| Other Expenses | ₹9.67 Cr | ₹6.3 Cr | ₹9.54 Cr | ₹10.32 Cr | ₹15.12 Cr | ₹15.52 Cr | ₹11.68 Cr | ₹17.23 Cr |
| Total Expenses | ₹59.06 Cr | ₹40.59 Cr | ₹42.49 Cr | ₹82.59 Cr | ₹78.98 Cr | ₹62.26 Cr | ₹61.42 Cr | ₹79.7 Cr |
| Profit Before Exceptional Items & Tax | ₹1.93 Cr | ₹3.1 Cr | ₹3.42 Cr | ₹13.4 Cr | ₹3.56 Cr | ₹8.87 Cr | ₹7.63 Cr | ₹16.26 Cr |
| Exceptional Items | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Profit Before Tax | ₹1.93 Cr | ₹3.1 Cr | ₹3.42 Cr | ₹13.4 Cr | ₹3.56 Cr | ₹8.87 Cr | ₹7.63 Cr | ₹16.26 Cr |
| Total Tax Expense | ₹54.91 Lakh | ₹1.18 Cr | ₹69 Lakh | ₹3.4 Cr | ₹1.1 Cr | ₹2.37 Cr | ₹2.14 Cr | ₹4.08 Cr |
| Net Profit | ₹1.38 Cr | ₹1.92 Cr | ₹2.73 Cr | ₹10 Cr | ₹2.28 Cr | ₹6.5 Cr | ₹5.49 Cr | ₹12.18 Cr |
| Other Comprehensive Income | ₹6.18 Lakh | ₹9.47 Lakh | ₹6.49 Lakh | -₹3 Lakh | ₹21 Lakh | -₹5 Lakh | -₹5 Lakh | -₹5 Lakh |
| Total Comprehensive Income | ₹1.44 Cr | ₹2.01 Cr | ₹2.79 Cr | ₹9.97 Cr | ₹2.49 Cr | ₹6.45 Cr | ₹5.44 Cr | ₹12.13 Cr |
| EBITDA (computed) | ₹4.48 Cr | ₹5.75 Cr | ₹6.55 Cr | ₹16.88 Cr | ₹6.86 Cr | ₹12.14 Cr | ₹10.26 Cr | ₹18.89 Cr |
| Basic EPS | ₹2.00 | ₹2.78 | ₹3.96 | ₹14.51 | ₹3.48 | ₹8.30 | ₹7.90 | ₹20.26 |
| Diluted EPS | ₹2.00 | ₹2.78 | ₹3.96 | ₹14.51 | ₹3.48 | ₹8.30 | ₹7.90 | ₹0.00 |
Shareholding Pattern of Bharat Parenterals Limited
As per the shareholding pattern filed with BSE for the quarter ended Mar 2026, promoters hold 67.17%, foreign institutional investors hold 0.11%, domestic institutional investors hold 1.06%, retail and other public shareholders hold 31.66% of Bharat Parenterals Limited. The company had 3,095 shareholders on record.
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | |
|---|---|---|---|---|---|---|
| Promoters | 67.17% | 67.19% | 67.19% | 67.19% | 67.20% | 67.20% |
| Public | 32.83% | 32.81% | 32.81% | 32.81% | 32.80% | 32.80% |
| Mar 2026 | Mar 2025 | Mar 2024 | |
|---|---|---|---|
| Promoters | 67.17% | 67.20% | 73.27% |
| Public | 32.83% | 32.80% | 26.73% |
| Promoter change (YoY, %pts) | -0.03 | -6.07 | - |
Group Structure of Bharat Parenterals Limited
Bharat Parenterals Limited has 2 subsidiary companies and 1 associated company. This group structure data is as of FY 2024. The corporate group structure reflects Bharat Parenterals Limited's business expansion strategy and organizational complexity.
| Company Name | CIN | Shares Held |
|---|---|---|
| Innoxel Lifesciences Private Limited | U24290GJ2020PTC117407 | - |
| Varenyam Biolifesciences Private Limited | U24290GJ2022PTC133332 | - |
Showing major subsidiaries. Total: 2.
Charges & Borrowings of Bharat Parenterals Limited
| Date | Lender | Amount | Status |
|---|---|---|---|
| 26 Nov 2025 | Hdfc Bank Limited | ₹12.86 Lakh | Open |
| 16 Dec 2024 | Hdfc Bank Limited | ₹21.5 Lakh | Open |
| 21 Sep 2024 | Hdfc Bank Limited | ₹78 Lakh | Open |
| 31 Jul 2024 | Hdfc Bank Limited | ₹70.3 Lakh | Open |
| 06 Jul 2024 | Axis Bank Limited | ₹25 Cr | Open |
Total charge records: 38 View all charges
Employees and EPFO Compliance at Bharat Parenterals Limited
Bharat Parenterals Limited has a workforce of 396 employees as of Dec 08, 2025.
Employee Count & EPFO Data of Bharat Parenterals Limited
Access employee headcount trends, monthly PF payment records, EPFO establishment details, and compliance data.
GST Compliance of Bharat Parenterals Limited
GSTIN & GST Filing Data of Bharat Parenterals Limited
Access GSTIN registrations, state-wise filing compliance, HSN/SAC codes, and detailed goods & services data.
Credit Ratings, Litigation & Regulatory Alerts for Bharat Parenterals Limited
Credit Ratings, Legal Cases & Regulatory Alerts of Bharat Parenterals Limited
Access complete credit rating history, litigation records, regulatory alerts, and compliance data.
MSME Payment Delays by Bharat Parenterals Limited
MSME Payment Delays by Bharat Parenterals Limited
Track payments outstanding to micro and small enterprise vendors, as disclosed in half-yearly MSME-1 returns filed with the MCA.
Subsidiaries & Group Companies of Bharat Parenterals Limited
Subsidiaries & Group Companies of Bharat Parenterals Limited
See the full corporate group - holding company, subsidiaries, associates and joint ventures of Bharat Parenterals Limited with ownership details.
MCA Filings & Documents of Bharat Parenterals Limited
MCA Filings & Documents of Bharat Parenterals Limited
Download official documents filed with the Ministry of Corporate Affairs - from incorporation papers to the latest annual filings.
Recent Activity on Bharat Parenterals Limited
Frequently Asked Questions about Bharat Parenterals Limited
Bharat Parenterals Limited is an active public limited company in the pharma sector based in Vadodara, Gujarat, India. It was incorporated on 03 September 1992 (34+ years old) and is registered under CIN L24231GJ1992PLC018237. Listed on BSE: 541096. The company has 396 employees.
Bharat Parenterals Limited reported revenue of ₹352 Cr for FY 2025 (up 32.00% YoY).
The current directors of Bharat Parenterals Limited are:
- Mukeshbhai Jivrajbhai Patel
- Jignesh Nitinchandra Shah
- Bharatkumar Rameshchandra Desai
- Shaileshkumar Ghabhawala
- Zankhana Bimalkumar Sheth
- Hemang Jayendrabhai Shah
- Sharmin Nareshkumar Soni
- Alkesh Jayantilal Shah
The primary industry of Bharat Parenterals Limited is pharma. The company specifically operates in drug formulation and development. The company is currently active in this sector.
Yes. Bharat Parenterals Limited is listed on BSE with code 541096.
Bharat Parenterals Limited can be reached at the registered office: Survey No. 144A Jarod – Samlaya Road Haripura Savli, Vadodara, Gujarat, India – 391520, or through the website bplindia.in.